Trial Outcomes & Findings for Randomized Control Trial of a Topical Anesthetic to Evaluate Pain and Anxiety During Venipuncture (NCT NCT00676364)

NCT ID: NCT00676364

Last Updated: 2012-09-25

Results Overview

Pain was measured immediately after venipuncture by the participant using the six-point FACES scale. "FACES" in not an acronym, but rather a description of a pain scale that uses pictures of faces in various states of pain. The FACES pain scale is a common scale used to measure pain with scores on a scale. The scale we used had six points from zero (0) to five (5) indicating different levels of pain. Lower scores indicate lower levels of pain, and higher scores indicate higher levels of pain.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

114 participants

Primary outcome timeframe

Pain was measured immediately after venipuncture.

Results posted on

2012-09-25

Participant Flow

The study was conducted at one site of a multi-site, academic, community emergency department. Children between the ages of five and 18 years of age were considered for enrollment into the study if they were seen in the emergency department (ED) and a physician order was placed for intravenous cannulation or labs to be drawn by venipuncture.

A convenience sample was utilized due to the availability of the research study coordinator who completed the enrollment from 7 am to 5 pm Monday through Friday. One participant was excluded from analysis due to ineligibility.

Participant milestones

Participant milestones
Measure
ControI Group Receiving Placebo Cream
Control group receiving blinded placebo cream under occlusive dressing prior to venipuncture
Investigational Group Receiving 4% Lidocaine
Investigational group receiving blinded 4% lidocaine cream under occlusive dressing for 15 mins prior to venipuncture
Overall Study
STARTED
57
57
Overall Study
COMPLETED
57
57
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Randomized Control Trial of a Topical Anesthetic to Evaluate Pain and Anxiety During Venipuncture

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ControI Group Receiving Placebo Cream Before Venipuncture
n=57 Participants
Experimential group receiving medicated topical cream prior to venipuncture
Investigational Group
n=57 Participants
Investigational group receiving blinded 4% lidocaine cream
Total
n=114 Participants
Total of all reporting groups
Age, Categorical
<=18 years
57 Participants
n=5 Participants
57 Participants
n=7 Participants
114 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age Continuous
11.6 years
STANDARD_DEVIATION 3.7 • n=5 Participants
11.6 years
STANDARD_DEVIATION 3.7 • n=7 Participants
11.6 years
STANDARD_DEVIATION 3.7 • n=5 Participants
Sex: Female, Male
Female
35 Participants
n=5 Participants
35 Participants
n=7 Participants
70 Participants
n=5 Participants
Sex: Female, Male
Male
22 Participants
n=5 Participants
22 Participants
n=7 Participants
44 Participants
n=5 Participants
Region of Enrollment
United States
57 participants
n=5 Participants
57 participants
n=7 Participants
114 participants
n=5 Participants

PRIMARY outcome

Timeframe: Pain was measured immediately after venipuncture.

Population: We determined that we will need to enroll 43 children in each group, for a power of .80, alpha=0.05. We used a per protocol analysis.

Pain was measured immediately after venipuncture by the participant using the six-point FACES scale. "FACES" in not an acronym, but rather a description of a pain scale that uses pictures of faces in various states of pain. The FACES pain scale is a common scale used to measure pain with scores on a scale. The scale we used had six points from zero (0) to five (5) indicating different levels of pain. Lower scores indicate lower levels of pain, and higher scores indicate higher levels of pain.

Outcome measures

Outcome measures
Measure
ControI Group Receiving Placebo Cream
n=57 Participants
Control group receiving placebo topical cream prior to venipuncture
Investigational Group
n=57 Participants
Investigational group receiving 4% lidocaine cream prior to venipuncture
Pain From Venipuncture
2.2 scores on a scale
Standard Deviation 1.4
2.1 scores on a scale
Standard Deviation 1.6

SECONDARY outcome

Timeframe: During venipuncture

Population: We determined that we will need to enroll 43 children in each group, for a power of .80, alpha=0.05. We used a per protocol analysis.

Participant anxiety was measured by the study participant and the objective observer before (anticipatory), during (venipuncture) and after (recovery) venipuncture using a validated visual analog scale (VAS). The VAS is a validated scale that is used to detect small changes in many types of observations. The scale ranges from 0-100 scores on a scale, and here the higher scores indicate higher anxiety levels. Only the participant's mean venipuncture (during venipuncture) anxiety scores are presented in outcome measure results here.

Outcome measures

Outcome measures
Measure
ControI Group Receiving Placebo Cream
n=57 Participants
Control group receiving placebo topical cream prior to venipuncture
Investigational Group
n=57 Participants
Investigational group receiving 4% lidocaine cream prior to venipuncture
Anxiety of Venipuncture
43.1 scores on a scale
Standard Deviation 36.5
40.5 scores on a scale
Standard Deviation 36.4

Adverse Events

ControI Group Receiving Placebo Cream

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Investigational Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jenny Boucher

Lehigh Valley Health Network

Phone: 610-402-8844

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place